Le Lézard
Classified in: Health
Subject: MAT

Dr. Alexander Rivkin is Proud to Announce That Westside Aesthetics is One of the First Clinics to Offer Newly FDA-Approved JUVÉDERM® VOLUXtm XC


Westside Aesthetics in Los Angeles, CA, the premier global destination for facial and dermal filler treatments, is excited to provide this breakthrough in the aesthetic product world.

LOS ANGELES, Aug. 30, 2022 /PRNewswire-PRWeb/ -- At Westside Aesthetics, Alexander Z. Rivkin, M.D. and his team specialize in perfecting and popularizing state-of-the-art non-surgical facial sculpting procedures. JUVÉDERM® VOLUXtm XC is the first hyaluronic acid-based injectable filler approved by the FDA that specifically targets the jawline, a key area of concern for many consumers. This brand-new hyaluronic acid filler will last more than a year and is firmer and higher in viscosity, or thickness, than other HA fillers designed for the lips, cheeks and chin. Like all HA fillers, JUVÉDERM® VOLUXtm XC can be reversed, if needed, using an enzyme known as hyaluronidase. According to press materials, JUVÉDERM® VOLUXtm XC provides more structure, cohesivity and lift capacity to create an improved jawline that appears more defined. Westside Aesthetics offers a wide variety of cosmetic procedures, from non-surgical rhinoplasty to injectable fillers, Botox, laser procedures and energy-based skin tightening treatments. Dr. Rivkin is considered a global expert on non-surgical facial aesthetic treatments and is dedicated to developing and optimizing revolutionary new procedures, using the latest FDA-approved injectable fillers and toxins.

"I am thrilled to be able to offer this innovative treatment option to my patients seeking an improved jawline," says Dr. Alexander Rivkin. "I am equally excited to explore the potential of this filler in other areas of the face. I think it will be a game changer for non-surgical facial sculpting!"

More about Dr. Alexander Rivkin:

Alexander Z. Rivkin, MD is a facial aesthetic specialist and Assistant Clinical Professor at the David Geffen / UCLA School of Medicine. His practice, Westside Aesthetics, is focused on developing and perfecting non-invasive, non-ablative cosmetic treatments. He is best known nationally for pioneering and popularizing the Non-Surgical Rhinoplasty procedure. In 2020 he authored the largest statistically comprehensive study on Non-Surgical Rhinoplasty in the global medical literature.

Dr. Rivkin received his undergraduate degree from Columbia University and his medical degree from the Yale University School of Medicine. His residency in Otolaryngology/ Head and Neck Surgery was at the University of California San Diego School of Medicine.

Dr. Rivkin has authored numerous peer-reviewed publications and chapters on non-surgical cosmetic treatments and serves as a lead investigator on FDA and NIH clinical trials on a regular basis. He frequently trains physicians from all over the world on optimizing advanced injection techniques and serves as an expert for national media, including the TODAY show, The Doctors, Good Morning America, Entertainment Tonight and EXTRA.

Dr. Rivkin divides his time between patient care, clinical research, physician education, media appearances, and lecturing at scientific conferences throughout the world.

Media Contact

Nico Stahl, Westside Aesthetics, 310-443-5273, [email protected]

 

SOURCE Westside Aesthetics


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: